-- New Life Scientific, Inc.
15 Roszel Road North
Princeton, NJ 08543
Phone: (732) 303-7341
Business Description: Biotech
Primary State of Incorporation: Nevada
Country of Incorporation: USA
Henry Val, CEO
About New Life Scientific, Inc.
New Life Scientific, Inc. (NWLS) is a developmental biotech company whose core focus is to develop and commercialize novel biotech/pharmaceutical products including stem cell based treatment modalities and to expand through our own research, collaborations, acquisitions and in-licensing. NWLS utilizes its strategic geographical positioning in Europe to seek undiscovered, emerging and under-valued biotechnologies with the further intent of their commercialization. Our goal is to become a leader in both the development and commercialization of innovative drugs and drug delivery products and technologies. We will focus our research and development efforts on product candidates using proprietary technologies for drug delivery including targeted drug release from oral route of administration and utilizing tight junctions in topical drug delivery, which may offer significant clinical advantages such as improved safety and clinical efficacy or increased patient compliance due to elimination of injection site pain and avoidance of injection site irritation. We will continue to try to establish strategic collaborations with leading pharmaceutical and biotechnology companies. In select cases where we deem it to be strategically advantageous to us, we plan to internally develop, manufacture and distribute our products. We have invested substantial time, intellectual capital and finances in expanding our research and know-how which we believe would be difficult for our competitors to replicate in the near term. NWLS has three subsidiaries: PharmaTrials International (PTI)
, a provider of services to pharmaceutical industry in the areas of clinical trials, regulatory approvals and the market research of products for pharmaceutical, biotech and medical device companies worldwide; Invamed Pharma, with expertise in development and commercialization of pharmaceutical/biotech products originating from its own pipeline of in-licensed and new therapeutic classes as well as reformulation of existing products to improve their therapeutic potential. New Life's objective is to utilize Western management and marketing procedures to bring these discoveries to those who need them utilizing cost containment and in a commercially profitable manner.
Pharma Trials International
provides services in areas of clinical and market research as well as regulatory support to pharmaceutical clients and other Contract Research Organizations (CROs). PTI assists pharmaceutical, biotechnology, and medical device companies with management for their clinical research programs. A CRO is a company that is contracted to perform all or part of sponsor's clinical trials-related tasks. This might include the design, monitoring, and management of trials, the analysis of results, and other specialty duties that drug developers do not have the capacity to perform efficiently.
is engaged in the development and marketing of biopharmaceutical products and will conduct its clinical trials through Pharma Trials International, Inc., a wholly owned subsidiary of New Life.
a joint venture company with Biorigen Srl, (Genoa, Italy), a Biotech Company and Centro Biotecnologie Avanzate (Genoa, Italy) to pursue development of a series of research projects, the first one being the project of "Bone Repair by Tissue Engineering" that is using novel biotechnology. Under the agreement, BIORIGEN USA, Inc obtains global rights with Biorigen Srl retaining rights for the European Union and countries of the Mediterranean Basin and Middle East countries.
CEO, Ch of the Board
Wieslaw J. Bochenek, M.D., Ph.D.
President & Director
Eugene Zabolotsky, MBA
VP & Director
VP PTI Operations
Scientific Board of Advisors
Khurshid Iqbal, PhD.
Ranieri Cancedda, M.D. PhD
Jerry Piotrowski, M.D, PhD
Outstanding Shares: 51,620,540 as of March 31, 2007